Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burger

Showing results (811-820 of 1,123) with videos related to

Pageof 113
Sort By:
World Journal of Urology|May 18, 2021
The HELENA study: Hexvix<sup>®</sup>-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority studyM Gierth, J Breyer, F Zeman, et al.
British Journal of Clinical Pharmacology|January 13, 2017
Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysisEsther J H Janssen, Diane E T Bastiaans, Pyry A J Välitalo, et al.
AIDS (London, England)|May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tabletsHanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 15, 2022
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancerLeila S Otten, Berber Piet, Michel M van den Heuvel, et al.
Natural Product Research|January 28, 2015
Evaluation of flavonols and derivatives as human cathepsin B inhibitorSuelem D Ramalho, Lorena R F de Sousa, Marcela C M Burger, et al.
Antiviral Therapy|March 27, 2009
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA studyMatthijs van Luin, Wendy P Bannister, Amanda Mocroft, et al.
AIDS Research and Human Retroviruses|October 4, 2013
Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patientsAnchalee Avihingsanon, Stephen J Kerr, Baralee Punyawudho, et al.
Lung Cancer (Amsterdam, Netherlands)|June 7, 2020
Cumulative pemetrexed dose increases the risk of nephrotoxicityN de Rouw, R J Boosman, H van de Bruinhorst, et al.
Gynecologic Oncology|February 23, 2010
Long-term cervical cancer survivors suffer from pelvic floor symptoms: a cross-sectional matched cohort studyM H Hazewinkel, M A G Sprangers, J van der Velden, et al.
British Journal of Clinical Pharmacology|November 26, 2004
Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteersC J L la Porte, M J A de Graaff-Teulen, E P H Colbers, et al.
Pageof 113

Showing results (811-820 of 1,123) with videos related to

Sort By:
Pageof 113
World Journal of Urology|May 18, 2021
The HELENA study: Hexvix<sup>®</sup>-TURB vs. white-light TURB followed by intravesical adjuvant chemotherapy-a prospective randomized controlled open-label multicenter non-inferiority studyM Gierth, J Breyer, F Zeman, et al.
British Journal of Clinical Pharmacology|January 13, 2017
Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysisEsther J H Janssen, Diane E T Bastiaans, Pyry A J Välitalo, et al.
AIDS (London, England)|May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tabletsHanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 15, 2022
Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancerLeila S Otten, Berber Piet, Michel M van den Heuvel, et al.
Natural Product Research|January 28, 2015
Evaluation of flavonols and derivatives as human cathepsin B inhibitorSuelem D Ramalho, Lorena R F de Sousa, Marcela C M Burger, et al.
Antiviral Therapy|March 27, 2009
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA studyMatthijs van Luin, Wendy P Bannister, Amanda Mocroft, et al.
AIDS Research and Human Retroviruses|October 4, 2013
Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patientsAnchalee Avihingsanon, Stephen J Kerr, Baralee Punyawudho, et al.
Lung Cancer (Amsterdam, Netherlands)|June 7, 2020
Cumulative pemetrexed dose increases the risk of nephrotoxicityN de Rouw, R J Boosman, H van de Bruinhorst, et al.
Gynecologic Oncology|February 23, 2010
Long-term cervical cancer survivors suffer from pelvic floor symptoms: a cross-sectional matched cohort studyM H Hazewinkel, M A G Sprangers, J van der Velden, et al.
British Journal of Clinical Pharmacology|November 26, 2004
Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteersC J L la Porte, M J A de Graaff-Teulen, E P H Colbers, et al.
Pageof 113